Target Information
| Target General Infomation | |||||
|---|---|---|---|---|---|
| Target ID |
T60345
|
||||
| Target Name |
T-cell surface glycoprotein CD3
|
||||
| Target Type |
Clinical Trial
|
||||
| Disease | Acute lymphoblastic leukemia; Acute myeloid lymphoma [ICD9:204.0, 556; ICD10: C91.0, C92.0] | ||||
| Acute lymphoblastic leukemia [ICD9: 204.0, 556; ICD10: C91.0] | |||||
| Non-hodgkin's lymphoma [ICD10: C85] | |||||
| Type 1 diabetes [ICD9: 250; ICD10: E10] | |||||
| BioChemical Class |
Antigen
|
||||
| Drugs and Mode of Action | |||||
| Drug(s) | Blinatumomab | Drug Info | Approved | Acute lymphoblastic leukemia | [1], [2] |
| Otelixizumab | Drug Info | Phase 2 | Type 1 diabetes | [3], [4] | |
| CD20Bi aATC | Drug Info | Phase 1 | Non-hodgkin's lymphoma | [5] | |
| MGD006 | Drug Info | Phase 1 | Acute lymphoblastic leukemia; Acute myeloid lymphoma | [6], [7] | |
| Modulator | Blinatumomab | Drug Info | [8] | ||
| CD20Bi aATC | Drug Info | [5] | |||
| MGD006 | Drug Info | [6] | |||
| Otelixizumab | Drug Info | ||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | ||||
| REF 2 | ClinicalTrials.gov (NCT02393859) Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL | ||||
| REF 3 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8458). | ||||
| REF 4 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018350) | ||||
| REF 5 | CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933. | ||||
| REF 6 | A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87. | ||||
| REF 7 | ClinicalTrials.gov (NCT02152956) Safety Study of MGD006 in Relapsed/Refractory Acute Myeloid Leukemia (AML) or Intermediate-2/High Risk MDS | ||||
| REF 8 | 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.